Next-generation therapy for follicular lymphoma
- PMID: 30287467
- DOI: 10.1182/blood-2018-08-868117
Next-generation therapy for follicular lymphoma
Conflict of interest statement
Conflict-of-interest disclosure: The author declares no competing financial interests.
Comment on
-
An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.Blood. 2018 Oct 4;132(14):1486-1494. doi: 10.1182/blood-2018-05-853499. Epub 2018 Aug 1. Blood. 2018. PMID: 30068505 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources

